Facile fabrication of selegiline-loaded alginate hydrogel for neuroprotection and functional recovery in a rat model of spinal cord injury through localized spinal delivery

Document Type : Original Article

Authors

1 Research Center for Trauma in Police Operations, Directorate of Health, Rescue & Treatment, Police Headquarters, Tehran, Iran

2 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

3 Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

4 Toxicology and Diseases Specialty Group, Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, Iran

5 Department of Support and Services Management, Institute of Management and Organizational Resources, Policing Sciences and Social Studies Research Institute, Tehran, Iran

6 Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran

7 Neurosurgery Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

8 Valiasr Hospital, Department of Neurosurgery, Tehran, Iran

Abstract

Objective(s): Spinal cord injury (SCI) is a highly disabling and fatal disorder with no effective treatment to date. Selegiline, a selective MAO-B inhibitor, has shown new neuroprotective and neurorescuing effects with various beneficial effects on neuron-associated disorders. These effects have triggered investigations into its impact on different neuron-associated disorders and SCI. Thus, in continuation of the previous studies, this study evaluates the local therapeutic effects of selegiline-loaded alginate hydrogel on SCI by analyzing apoptotic factors, histological factors, and improvements in locomotor function and neuropathic pain.
Materials and Methods: Hydrogels were fabricated via cross-linking gelation method and characterized by FT-IR and SEM analysis. Selegiline release from hydrogels was evaluated by UV spectroscopy, and hydrogel biocompatibilities were verified through an MTT assay. Afterward, 36 rats were divided into six groups: sham, negative group, treated with empty hydrogel, and three selegiline-treated groups (2.5, 5, and 10 mg/kg). After 28 days, the locomotor activity, the expression of Bax and Bcl2 (apoptosis index), and GFAP changes in the lesion site were assessed using Basso, Beattie, and Bresnahan (BBB) scale, western blot technique, and immunohistochemical assay, respectively.
Results: Hydrogel tests showed the suitability of hydrogels and sustained selegiline release from them. Rats treated with selegiline-loaded hydrogels showed significant locomotor improvement and reduced apoptosis indices in SCI-induced rats (P≤0.05). Additionally, GFAP immunohistochemistry analysis indicated notable histological improvements. 
Conclusion: Findings suggest that selegiline-loaded hydrogels can improve SCI through apoptosis inhibition and neurorescuing effects. Further clinical studies are warranted to validate these findings in human SCI.

Keywords

Main Subjects

References

1. Sun J, Yuan W, Zheng R, Zhang C, Guan B, Ding J, et al. Traumatic spinal injury-related hospitalizations in the United States, 2016-2019: A retrospective study. Int J Surg 2023; 109: 3827-3835. 
2. Eckert MJ, Martin MJ. Trauma: Spinal cord injury. Surg Clin North Am 2017; 97: 1031-1045. 
3. Center NS. Spinal cord injury 2016 facts and figures at a glance. J Spinal Cord Med 2016; 39: 493-494. 
4. McDaid D, Park AL, Gall A, Purcell M, Bacon M. Understanding and modelling the economic impact of spinal cord injuries in the United Kingdom. Spinal Cord 2019; 57: 778-788. 
5. Ding W, Hu S, Wang P, Kang H, Peng R, Dong Y, et al. Spinal cord injury: The global incidence, prevalence, and disability from the global burden of disease study 2019. Spine (Phila Pa 1976) 2022; 47: 1532-1540.
6. Bustos ML, Huleihel L, Kapetanaki MG, Lino-Cardenas CL, Mroz L, Ellis BM, et al. Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response. Am J Respir Crit Care Med 2014; 189: 787-798. 
7. Cooke P, Janowitz H, Dougherty SE. Neuronal redevelopment and the regeneration of neuromodulatory axons in the adult mammalian central nervous system. Front Cell Neurosci 2022; 16: 872501-872818. 
8. Fehlings MG, Wilson JR, Cho N. Methylprednisolone for the treatment of acute spinal cord injury: Counterpoint. Neurosurgery 2014; 61: 36-42. 
9. Ozkunt O, Sariyilmaz K, Gemalmaz HC, Gürgen SG, Yener U, Dikici F. Investigation of efficacy of treatment in spinal cord injury: Erythropoietin versus methylprednisolone. J Orthop Surg (Hong Kong) 2017; 25: 2309499017739481. 
10. Walters BC, Hadley MN, Hurlbert RJ, Aarabi B, Dhall SS, Gelb DE, et al. Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update. Neurosurgery 2013; 60: 82-91. 
11. Lima R, Monteiro A, Salgado AJ, Monteiro S, Silva NA. Pathophysiology and therapeutic approaches for spinal cord injury. Int J Mol Sci 2022; 23:13833-13864. 
12. Knoll J. Deprenyl (selegiline): The history of its development and pharmacological action. Acta Neurol Scand Suppl 1983: 95: 57-80. 
13. Lu D, Johnson C, Johnson S, Tazik S, Ou XM. The neuroprotective effect of antidepressant drug via inhibition of TIEG2-MAO B mediated cell death. Drug Discov Ther 2008; 2: 289-295. 
14. Filip V, Kolibás E. Selegiline in the treatment of Alzheimer’s disease: A long-term randomized placebocontrolled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 1999; 24: 234-243. 
15. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, et al. L-deprenyl in Alzheimer’s disease: Cognitive and behavioral effects. Neurology 1998; 50: 660-668. 
16. Nikfar A, Abdanipour A, Gholinejad M. Anti-apoptotic effect of selegiline as monoamine oxidase inhibitor on rat hippocampus derived neural stem cells in oxidative stress condition. J Adv Med Biomed Res 2017; 25: 41-56. 
17. Tatton W. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993; 8: S20-S30. 
18. Ebadi M, Sharma S, Shavali S, El Refaey H. Neuroprotective actions of selegiline. J Neurosci Res 2002; 67: 285-289. 
19. Stern G. Neuroprotection by selegiline and other MAO inhibitors. J Neural Transm Suppl 1998; 99-107. 
20. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000; 279: 751-755. 
21. Amiri A, Kashani MHG, Ghorbanian MT. Expression of neurotrophic factor genes by human adipose stem cells post-induction by deprenyl. Anat Cell Biol 2021; 54: 74-82. 
22. Amini H, Heshmati M, Jalali M. The study of the effect of deprenyl on gliosis after spinal cord compression in adult rat. Daneshvar Med 2020; 16: 27-36.
23. Fan G, Luan J, Tang X, Song Q. Bethanechol versus selegiline in amelioration of spinal cord injury in a rat model: A potential therapeutic option in spinal cord injury treatment. Trop J Pharm Res 2020; 19: 83-87. 
24. Villarinho JG, Oliveira SM, Silva CR, Cabreira TN, Ferreira J. Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice. Eur J Pharmacol 2012; 690: 107-114. 
25 Izadpanah E, Fathi F, Rezaie MJ, Asgari A. Assessment of functional recovery of contusive spinal cord injury by administration of (-)-Deprenyl in rats. Sci J Kurdistan Univ Med Sci 2009; 14: 1-10. 
26. Lehrer S, Rheinstein PH. Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer’s disease: A new route of administration. Discov Med 2019; 27: 37-43. 
27. Gholami M, Gilanpour H, Sadeghinezhad J, Asghari A. Facile fabrication of an erythropoietin-alginate/chitosan hydrogel and evaluation of its local therapeutic effects on spinal cord injury in rats. Daru 2021; 29: 255-265. 
28. McEllistrem RF, Bennington RG, Roth SH. In vitro determination of human dura mater permeability to opioids and local anaesthetics. Can J Anaesth 1993; 40: 165-169. 
29. Heinonen EH, Lammintausta R. A review of the pharmacology of selegiline. Acta Neurol Scand Suppl 1991; 136: 44-59. 
30. Sitoci-Ficici KH, Matyash M, Uckermann O, Galli R, Leipnitz E, Later R, et al. Non-functionalized soft alginate hydrogel promotes locomotor recovery after spinal cord injury in a rat hemimyelonectomy model. Acta Neurochir (Wien). 2018; 160: 449-457. 
31. Grijalvo S, Nieto-Díaz M, Maza RM, Eritja R, Díaz DD. Alginate hydrogels as scaffolds and delivery systems to repair the damaged spinal cord. Biotechnol J 2019; 14: 1900275. 
32. Semkova I, Wolz P, Schilling M, Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 1996; 315: 19-30. 
33. Hussain AM, Renno WM, Sadek HL, Kayali NM, Al-Salem A, Rao MS, et al. Monoamine oxidase-B inhibitor protects degenerating spinal neurons, enhances nerve regeneration and functional recovery in sciatic nerve crush injury model. Neuropharmacology 2018; 128: 231-243. 
34. Abdanipour A, Nikfar A, Nikbakht Rad M, Jafari Anarkooli I, Mansouri M. Neuroprotective effect of L-deprenyl on the expression level of the Mst1 gene and inhibition of apoptosis in rat-model spinal cord injury. Iran J Basic Med Sci 2022; 25: 53-59. 
35. Afshari K, Dehdashtian A, Haddad NS, Jazaeri SZ, Ursu DC, Khalilzadeh M, et al. Sumatriptan improves the locomotor activity and neuropathic pain by modulating neuroinflammation in rat model of spinal cord injury. Neurol Res 2021; 43: 29-39. 
36. Afshari K, Dehdashtian A, Haddadi NS, Haj-Mirzaian A, Iranmehr A, Ebrahimi MA, et al. Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy. Spinal Cord 2018; 56: 1032-1041. 
37. Lajmiri E, Javdani M, Khosravian P, Hashemnia M, Mehrjerdi HK. Preparation and evaluation of controlled released implant containing mesoporous selenium nanoparticles loaded with curcumin in rats with spinal cord injury. Vet Res Forum 2024; 15: 357-367.
38. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma
1995; 12: 1-21.
39. Asadi M, Mohammadi-Khanaposhtani M, Hosseini FS, Gholami M, Dehpour AR, Amanlou M. Design, synthesis, and evaluation of novel racecadotril-tetrazole-amino acid derivatives as new potent analgesic agents. Res Pharm Sci 2021; 16: 341-357. 
40. Kukkar A, Singh N, Jaggi AS. Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats. J Formos Med Assoc 2014; 113: 921-928. 
41. Baeeri M, Momtaz S, Navaei-Nigjeh M, Niaz K, Rahimifard M, Ghasemi-Niri SF, et al. Molecular evidence on the protective effect of ellagic acid on phosalone-induced senescence in rat embryonic fibroblast cells. Food Chem Toxicol 2017; 100: 8-23. 
42. Galeshkalami NS, Abdollahi M, Najafi R, Baeeri M, Jamshidzade A, Falak R, et al. Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis. Life Sci 2019; 216: 101-110. 
43. Bali N, Salve PS. Fabrication and evaluation of selegiline HCl embedded transdermal film for management of Parkinson’s disease.J. Drug Delivery Ther 2019: 15:344-351.
44. Jafari B, Gharbavi M, Baghdadchi Y, Manjili HK, Mahmoudi J, Jafari-Anarkoli I, et al. Mitigated oxidative stress and cognitive impairments in transient global ischemia using niosomal selegiline‐nbp delivery. Behav Neurol 2022; 1: 4825472. 
45. Hafezi B, Kazemi Mehrjerdi H, Moghaddam Jafari A. Effect of captopril on paraplegia caused by spinal cord ischemia-reperfusion injury in rats. Vet Res Forum 2024; 15: 379-385.
46. Liu X, Zhang Y, Wang Y, Qian T. Inflammatory response to spinal cord injury and its treatment. World Neurosurg 2021; 155: 19-31. 
47. Yang Z, Wang KK. Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 2015; 38: 364-374. 
48. Feizipour S, Sobhani S, Mehrafza S, Gholami M, Motaghinejad M, Motevalian M, et al. Selegiline acts as neuroprotective agent against methamphetamine-prompted mood and cognitive related behavior and neurotoxicity in rats: Involvement of CREB/BDNF and Akt/GSK3 signal pathways. Iran J Basic Med Sci 2020; 23: 606-615. 
49. Fann JR, Bombardier CH, Richards JS, Tate DG, Wilson CS, Temkin N. Depression after spinal cord injury: comorbidities, mental health service use, and adequacy of treatment. Arch Phys Med Rehabil 2011; 92: 352-360. 
50. Ishikawa T, Okano M, Minami A, Tsunekawa H, Satoyoshi H, Tsukamoto Y, et al. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. Behav Brain Res 2019; 359: 353-361. 
51. Abdanipour A, Mirzaei M, Jafari Anarkooli I, Mohammadi P. Effect of selegiline as a monomine oxidase B inhibitor on the expression of neurotrophin mRNA levels in a contusion rat model of spinal cord injury. Neurol Res 2022; 45: 1-7. 
52. Javdani M, Khosravian P, Sadeghi M, Mohebi A. Design and local application of controlled released drug delivery system of chitosan hydrogel loaded with selenium nanoparticle in spinal cord injury-induced rat; evaluation of anti-oxidant changes in neural tissue. Iran J Veter Surg 2024; 8-16. 
53. Amanollahi S, Bahrami AR, Haghighitalab A, Yazdi HS, Mehrjerdi HK. Immediate administration of hTERT-MSCs-IDO1-EVs reduces hypoalbuminemia after spinal cord injury. Vet Res Forum 2024; 15: 27-34.
54. Ansorena E, De Berdt P, Ucakar B, Simón-Yarza T, Jacobs D, Schakman O, et al. Injectable alginate hydrogel loaded with GDNF promotes functional recovery in a hemisection model of spinal cord injury. Int J Pharm 2013; 455: 148-158.
55. Wang C-C, Yang K-C, Lin K-H, Liu H-C, Lin F-H. A highly organized threedimensional alginate scaffold for cartilage tissue engineering prepared by microfluidic technology. Biomaterials 2011; 32: 7118-7126. 
56. Al-Zyoud W, Haddadin D, Hasan SA, Jaradat H, Kanoun O. Biocompatibility testing for implants: A novel tool for selection and characterization. Materials 2023; 16: 6881-6913. 
57. Sahoo DR, Biswal T. Alginate and its application to tissue engineering. SN Applied Sci 2021; 3: 30-48. 
58. Jeon O, Powell C, Solorio LD, Krebs MD, Alsberg E. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparinalginate hydrogels. J Control Release 2011; 154: 258-266. 
59. Artusio F, Casà D, Granetto M, Tosco T, Pisano R. Alginate nanohydrogels as a biocompatible platform for the controlled release of a hydrophilic herbicide. Processes 2021; 9: 1641-1654. 
60. Huang X, Lowe TL. Biodegradable thermoresponsive hydrogels for aqueous encapsulation and controlled release of hydrophilic model drugs. Biomacromolecules 2005; 6: 2131-2139. 
61. Nazemi Z, Nourbakhsh MS, Kiani S, Heydari Y, Ashtiani MK, Daemi H, et al. Co-delivery of minocycline and paclitaxel from injectable hydrogel for treatment of spinal cord injury. J Control Release 2020; 321: 145-158. 
62. Ansari KS, Yu PH, Kruck TP, Tatton WG. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition. J Neurosci. 1993; 13: 4042-4053. 
63. Sur D, Dutta A, Mondal C, Banerjee A, Haldar PK, Maji HS, et al. Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stressmediated inflammatory cytokines. Inflammopharmacology. 2022; 30: 453-463. 
64. Bhawna, Kumar A, Bhatia M, Kapoor A, Kumar P, Kumar S. Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies. Eur J Med Chem 2022; 242: 114655. 
65. Magyar K, Szende B. (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004; 25: 233-242. 
66. Wang YF, Zu JN, Li J, Chen C, Xi C-Y, Yan JL. Curcumin promotes the spinal cord repair via inhibition of glial scar formation and inflammation. Neurosc Lett 2014; 560: 51-56. 
67. Leal-Filho MB. Spinal cord injury: From inflammation to glial scar. Surg Neurol Int 2011; 2: 112-120. 
68. Verkhratsky A, Butt A, Li B, Illes P, Zorec R, Semyanov A, et al. Astrocytes in human central nervous system diseases: A frontier for new therapies. Signal Transduct Target Ther 2023; 8: 396-432. 
69. Perez-Gianmarco L, Kukley M. Understanding the role of the glial scar through the depletion of glial cells after spinal cord injury. Cells 2023; 12: 1842-1858.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 5
May 2025
Pages 627-637

Files

Share

How to cite

Statistics